TW200621240A - Cancer treatments - Google Patents

Cancer treatments

Info

Publication number
TW200621240A
TW200621240A TW094138843A TW94138843A TW200621240A TW 200621240 A TW200621240 A TW 200621240A TW 094138843 A TW094138843 A TW 094138843A TW 94138843 A TW94138843 A TW 94138843A TW 200621240 A TW200621240 A TW 200621240A
Authority
TW
Taiwan
Prior art keywords
methods
cancer treatments
treatments
assessing
death
Prior art date
Application number
TW094138843A
Other languages
English (en)
Inventor
Heather Helene Bendall
Gary T Elliott
Lorenzo M Leoni
Christina Carol Niemeyer
Pratik S Multani
Original Assignee
Salmedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200621240(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salmedix Inc filed Critical Salmedix Inc
Publication of TW200621240A publication Critical patent/TW200621240A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW094138843A 2004-11-05 2005-11-04 Cancer treatments TW200621240A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62519304P 2004-11-05 2004-11-05
US66022605P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
TW200621240A true TW200621240A (en) 2006-07-01

Family

ID=36588320

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094138843A TW200621240A (en) 2004-11-05 2005-11-04 Cancer treatments

Country Status (12)

Country Link
US (2) US20060128777A1 (zh)
EP (1) EP1814544A4 (zh)
JP (1) JP2008519047A (zh)
CN (1) CN101933923A (zh)
AR (1) AR054094A1 (zh)
AU (1) AU2005317047A1 (zh)
CA (1) CA2585659A1 (zh)
CL (1) CL2009001721A1 (zh)
MX (1) MX2007005361A (zh)
NO (1) NO20072654L (zh)
TW (1) TW200621240A (zh)
WO (1) WO2006065392A2 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102304110A (zh) 2003-04-07 2012-01-04 Axys药物公司 作为治疗剂的异羟肟酸酯
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20090075967A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ceftriaxone
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
KR101707669B1 (ko) * 2008-04-17 2017-02-16 더 존스 홉킨스 유니버시티 약제-내성 종양에서 화학요법제 활성을 증강시키는 on01910.na
EP2889029A1 (en) * 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
MX2011005643A (es) * 2008-12-03 2011-09-27 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
CN102421451B (zh) * 2009-02-25 2013-11-06 休普拉特克药品有限公司 苯达莫司汀环多糖组合物
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
MX2011011109A (es) * 2009-04-28 2011-11-18 Cephalon Inc Formulaciones orales de bendamustina.
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US8609707B2 (en) 2010-01-28 2013-12-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2011151087A1 (en) * 2010-06-02 2011-12-08 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
PL2744515T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
EP2755648B1 (en) 2011-09-13 2017-03-08 Pharmacyclics LLC Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CN104011029B (zh) 2011-09-26 2016-06-08 费森尤斯卡比肿瘤学有限公司 一种制备盐酸苯达莫司汀的改进方法
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
SI2827862T1 (sl) 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
US10220051B2 (en) 2012-03-29 2019-03-05 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
US8927516B2 (en) * 2012-03-29 2015-01-06 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
EP3027192A4 (en) 2013-08-02 2017-03-22 Pharmacyclics, LLC Methods for the treatment of solid tumors
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
EP3052655B1 (en) 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
CA2941632C (en) * 2014-03-13 2023-10-24 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
JP2021515580A (ja) 2018-03-13 2021-06-24 オンクセオOnxeo がんの治療における獲得耐性に対抗するdbait分子
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
CA2149329C (en) * 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0725642B1 (en) * 1993-10-27 1999-12-01 PHARMACIA & UPJOHN COMPANY Stabilized prostaglandin e 1
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
GB9524334D0 (en) * 1995-11-28 1996-01-31 Philips Electronics Nv Mos transistor
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
NZ509376A (en) * 1998-07-09 2003-10-31 Francis A Nardella Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
PL362172A1 (en) * 2000-12-11 2004-10-18 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
CA2431319A1 (en) * 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
CA2462723C (en) * 2001-10-15 2012-05-01 Hemoteq Gmbh Coated stents for preventing restenosis
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
NZ536330A (en) * 2002-05-09 2007-08-31 Hemoteq Ag Medical devices such as stents comprising haemocompatible coating, production and use thereof
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
US6966329B2 (en) * 2003-01-27 2005-11-22 Hydraforce, Inc. Proportional pilot-operated flow control valve
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
US7157551B2 (en) * 2003-02-14 2007-01-02 Cephalon, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers

Also Published As

Publication number Publication date
US20060128777A1 (en) 2006-06-15
EP1814544A4 (en) 2009-12-02
MX2007005361A (es) 2008-01-11
AU2005317047A1 (en) 2006-06-22
CN101933923A (zh) 2011-01-05
AR054094A1 (es) 2007-06-06
NO20072654L (no) 2007-07-25
US20090209606A1 (en) 2009-08-20
WO2006065392A2 (en) 2006-06-22
WO2006065392A3 (en) 2006-12-21
JP2008519047A (ja) 2008-06-05
WO2006065392A8 (en) 2007-03-01
EP1814544A2 (en) 2007-08-08
CA2585659A1 (en) 2006-06-22
CL2009001721A1 (es) 2010-02-19

Similar Documents

Publication Publication Date Title
TW200621240A (en) Cancer treatments
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
WO2006081510A3 (en) Methods for treating renal cell carcinoma
PL1742644T3 (pl) Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
RS20050802A (en) Combinations for the treatment of diseases involving cell proliferation,migration or apoptosis of myeloma cells,or angiogeneis
WO2006015263A3 (en) Lonidamine analogs
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2006099261A3 (en) Potent and specific immunoproteasome inhibitors
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
IL177346A0 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
ATE510553T1 (de) Beta-2-glycoprotein 1 als angiogenesehemmer
WO2006096759A3 (en) Methods and compositions for treating cancer
WO2002102306A8 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists